<DOC>
	<DOCNO>NCT02078752</DOCNO>
	<brief_summary>To assess safety tolerability increase dose level PF-06647263 patient advance solid tumor order determine maximum tolerate dose select recommend Phase 2 dose .</brief_summary>
	<brief_title>A Study Of PF-06647263 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The clinical study include 2 part . Part 1 estimate MTD dose escalation cohort patient advance solid tumor standard therapy available order establish RP2D . Part 2 include patient previously treat metastatic triple negative breast cancer ( TNBC ) .</detailed_description>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Diagnosis solid tumor advanced/metastatic resistant standard therapy standard therapy available Performance Status 0 1 Adequate bone marrow , kidney , liver function Part 2 include advanced triple negative breast cancer patient . Brain metastases require steroid Major surgery , radiation therapy , systemic anticancer therapy within 4 week study treatment start Active clinically significant bacterial , fungal viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ADC</keyword>
	<keyword>PF-06647263</keyword>
	<keyword>solid tumor</keyword>
	<keyword>tumor</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>TNBC</keyword>
	<keyword>Triple negative breast cancer</keyword>
</DOC>